RET and non-small cell lung carcinoma: Two Chinese retrospective studies are investigating the putative role of ICI administered alone in second-line or further settings after progressing on TKI in 186 patients with gene-addicted NSCLC (NCT04777175) and in combination with CT (compared to CT alone) as first-line settings in 70 patients with RET fusion NSCLCs (POSEIDON NCT04322591).